Found: 3
Select item for more details and to access through your institution.
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
- Published in:
- Cancers, 2022, v. 14, n. 21, p. 5240, doi. 10.3390/cancers14215240
- By:
- Publication type:
- Article
Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 7, p. 1821, doi. 10.3390/cells10071821
- By:
- Publication type:
- Article
CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver.
- Published in:
- Nature Protocols, 2022, v. 17, n. 4, p. 1142, doi. 10.1038/s41596-021-00677-0
- By:
- Publication type:
- Article